In the TIGHT trial (n=110), CGM-guided intensive management aiming for 90 to 130 mg/dL did not lower mean glucose versus standard care (170 vs 175 mg/dL; P=0.25) in non-ICU adults with type 2 diabetes.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
In 39 patients newly starting glucocorticoids, median lumbar spine BMD at 12 months rose 8.6% with romosozumab, 3.3% with denosumab and fell 0.4% with a bisphosphonate; the trial was small and had no fracture endpoint.
SURMOUNT-1 at 3 years: tirzepatide lowered weight by 12.3 to 19.7% vs 1.3% on placebo, and progression to type 2 diabetes (HR 0.07) in prediabetes.
In a 16-person crossover trial, all light walking patterns lowered postprandial glucose and diastolic blood pressure versus sitting; only 30-minute continuous walks also lowered the insulin response.
In 55 older women with type 2 diabetes, pyridoxamine 200 mg twice daily missed its primary P1NP endpoint (P=0.056) but increased femoral neck BMD and lowered HbA1c in secondary analyses.
In the ElaTION trial secondary analysis (n=982), ultrasound alone had similar sensitivity to ultrasound plus FNAC (0.91 vs 0.87) but lower specificity (0.48 vs 0.67); 8% were discharged with U3 to U5 scans and non-diagnostic cytology.
In 131 adults aged 65 or older with type 1 diabetes and hypoglycaemia, CGM with geriatric principles cut time below 70 mg/dL by a median 2.3 points versus usual care (P<0.001) with no change in HbA1c.
In a phase 3 trial of 457 postmenopausal women, the proposed denosumab biosimilar SB16 showed lumbar spine BMD equivalent to reference denosumab at month 12 (difference 0.33%; 90% CI -0.25 to 0.91).
In 12 adults with type 1 diabetes, adding volagidemab to dapagliflozin raised time in range to 86% (vs 78% and 70%), cut insulin dose and lowered peak ketones versus dapagliflozin alone (2.0 vs 2.4 mmol/L).
In 85 adolescents from the CATS trial, global brain volumes, including total grey matter (P=0.373), did not differ by gestational thyroid status or maternal levothyroxine treatment.